

# ANALYSIS OF THE USE OF TERIFLUNOMIDE IN A TERTIARY HOSPITAL

C. Romero Delgado<sup>1</sup>, M. Suárez González<sup>2</sup>, M. Bullejos Molina<sup>1</sup>, I. Perera González<sup>1</sup>, G. Calzado Gómez<sup>1</sup>, J. González García<sup>1</sup>, J. Nazco Casariego<sup>1</sup>

<sup>1</sup>Hospital Universitario de Canarias <sup>2</sup>Hospital Ntra. Sra. de Candelaria  
Pharmacy Service, Tenerife, Spain.

## BACKGROUND

Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that inhibits the mitochondrial enzyme dehydroorotato-dehydrogenase (DHO-DH), which is required for the synthesis of pyrimidine, blocking the proliferation of activated B and T lymphocytes. It is believed that their therapeutic effect is related to the reduction in the number of lymphocytes. It is indicated for the treatment of adult patients with multiple sclerosis relapsing remitting with the advantage of oral administration.

## PURPOSE

To analyze the use of teriflunomide in patients diagnosed with multiple sclerosis



## MATERIAL AND METHODS

A retrospective observational study from January 2013 to May 2015. We used SAP program to evaluate the clinical history and dispensations of patients treated with teriflunomide. The following data were recorded: sex, age, EDSS, previous treatments, control of liver enzymes, kidney function, blood pressure, pregnancy test.

## RESULTS

18 patients, 17 women and 1 man were evaluated, with an average age of 41.11 years (range 23-79). Mean EDSS is 1.85 (1-5). All patients have records of blood pressure, blood count, kidney and liver function approximately every two weeks. Two patients began it before marketing. The reasons for the change were cutaneous adverse effects on local reaction at the injection site in all cases except dimethyl fumarate that was by digestive intolerance.

The average duration of treatment with teriflunomide is 3.77 months (1-20), without any abandonment of treatment by the time.



## CONCLUSION

While reports of teriflunomide therapeutic positioning is indicated at the forefront of relapsing remitting multiple sclerosis, only 29.41% of our patients were prescribed as first choice. Maybe, more and more patients with teriflunomide start in front given the comfort of the route of administration and good tolerance. Due to the short time to market required a longer-term review will be to verify the response to the drug.